Short-course Combivir after Single Dose Nevirapine Reduces But Does Not Eliminate the Emergence of Nevirapine-Resistance in Women

BACKGROUND: In TOPS trial, 4 or 7 days of Combivir (CBV; zidovudine/lamivudine) with maternal single dose nevirapine (sdNVP) significantly reduced the emergence of NVP resistance as determined by virus population genotype. To detect NVP resistance with greater sensitivity, we analyzed TOPS samples b...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Antivir Ther
Huvudupphovsmän: Palmer, Sarah, Boltz, Valerie F., Chow, Jeremy Y., Martinson, Neil A., McIntyre, James A., Gray, Glenda E., Hopley, Mark J., Mayers, Douglas, Robinson, Patrick, Hall, David B., Maldarelli, Frank, Coffin, John M., Mellors, John W.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2011
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6752704/
https://ncbi.nlm.nih.gov/pubmed/22293443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3851/IMP1946
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk